Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

Still, sitting ninth with one lap left in an overtime finish, the odds seemed against the driver of the No. 24 Chevrolet to escape the rest of the race unscathed, or even have enough time to pull ...

All absentee ballots must be submitted by 5 p.m. on May 20. The district also used the board meeting to celebrate its Regeneron Science Talent Search finalist, Sandeep Sawhney, and to recognize ...

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...

An enormous accomplishment no matter what your finish time or experience level, conquering a marathon is always worth the work that you put in. But in the midst of all your marathon training ...

SAN DIEGO (AP) — Denny McCarthy ended a miserable day in a most brilliant manner Thursday at the Genesis Invitational, closing birdie-eagle for a 4-under 68 on a Torrey Pines course that more ...

--(BUSINESS WIRE)--#CMO--Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics ...

Selkirk Pharma, a U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, has launched ClinFAST, a service designed to ...

A step-by-step guide to help you fill out a W-4 Thanasis / Getty Images You're about to begin that much-needed, new job and your employer hands you an IRS Form W-4 to fill out and submit to them ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.